Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA signs deal with Artios Pharma potentially worth up to $860m

Three-year collaboration agreement will seek to develop a range of therapeutic candidates

Merck KGaA has signed a strategic collaboration agreement with Artios Pharma to develop precision cancer medicines targeting DNA damage response pathways.

As part of the three-year strategic research collaboration agreement, the companies will utilise Artios’ nuclease targeting discovery platform to identify multiple targets for precision cancer drug candidates.

Under the terms of the agreement, Merck KGaA will pay Artios $30m upfront, as well as near-term payments. Artios will also be eligible to receive up to $860m per target if Merck KGaA chooses to exercise the option to develop and commercialise a candidate.

Artios could also receive royalty payments up to double digits on net sales of each product commercialised by Merck KGaA.

Artios’ management team are experts in the DNA damage response (DDR) field and were involved in developing olaparib, the first DDR inhibitor, now on its way to becoming a blockbuster for AstraZenca as Lynparza.

Cancer cells need nucleases – an enzyme involved in the maintenance of genomic integrity – to survive in response to DNA damage.

Additionally, in certain cancers that possess mutations in DNA damage response pathways, blocking key nucleases could result in the elimination of selective cancer cells, according to Merck KGaA.

"Targeting DNA damage response has the potential to provide an important therapeutic option for many patients in need of new treatments. We are excited about working with Artios to develop novel precision oncology medicines as we move towards changing the current paradigm in cancer treatment,” said Andree Blaukat, SVP and head of translational innovation platform oncology & immuno-oncology, at Merck KGaA.

"This collaboration further strengthens our leadership and expertise in the field and discovery of DDR inhibitors and complements our multiple innovative assets currently being evaluated in several phase 1 and phase 2 clinical studies," he added.

The Merck KGaA agreement does not include Artios’ lead pipeline programmes – including its DNA polymerase theta (Polθ) and ATR inhibitors.

Artios is planning to launch a first-in-human study for its Polθ inhibitor programme in 2021, while its ATR inhibitor is currently in preclinical testing.

Article by
Lucy Parsons

4th December 2020

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...